Elicio Therapeutics (ELTX) Common Equity (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Common Equity came in at -$1.4 million in Q1 2026, down 116.14% YoY from $8.9 million in Q1 2025, and down 187.84% on a QoQ basis from $1.6 million in Q4 2025.
Elicio Therapeutics (ELTX) Common Equity (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Common Equity data on file, last reported at -$1.4 million in Q1 2026.
- Quarterly Common Equity fell 116.14% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.4 million (down 116.14% YoY) and the FY2025 annual result came in at $1.6 million, up 114.46% from the prior year.
- Common Equity fell to -$1.4 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $23.6 million in Q2 2023 to a low of -$109.9 million in Q1 2023.
- A 5-year average of -$26.0 million and a median of -$1.4 million in 2026 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity slumped 248.34% — and 2025, when it surged 211.02%.
- Tracing ELTX's Common Equity over 5 years: stood at -$102.1 million in 2022, then jumped by 111.13% to $11.4 million in 2023, then plunged by 199.46% to -$11.3 million in 2024, then soared by 114.46% to $1.6 million in 2025, then plunged by 187.84% to -$1.4 million in 2026.
- The last three Common Equity figures came in at -$1.4 million (Q1 2026), $1.6 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | 7.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.94 Mn |
| Mar 31, 2026 | -1.44 Mn |
| Dec 31, 2025 | 1.64 Mn |
| Sep 30, 2025 | 3.82 Mn |
| Jun 30, 2025 | 1.83 Mn |
| Mar 31, 2025 | 8.90 Mn |
| Dec 31, 2024 | -11.31 Mn |
| Sep 30, 2024 | -18.99 Mn |
| Jun 30, 2024 | -1.65 Mn |
| Mar 31, 2024 | 4.87 Mn |
| Dec 31, 2023 | 11.37 Mn |
| Sep 30, 2023 | 13.29 Mn |
| Jun 30, 2023 | 23.56 Mn |
| Mar 31, 2023 | -109.88 Mn |
| Dec 31, 2022 | -102.15 Mn |
| Sep 30, 2022 | -95.70 Mn |
| Jun 30, 2022 | -88.62 Mn |
| Mar 31, 2022 | -81.44 Mn |
| Dec 31, 2021 | -74.54 Mn |
| Sep 30, 2021 | 64.51 Mn |